Moderna rises on Omicron-specific vaccine booster data

Booster

08/06/2022 12:33

** Shares of vaccine maker Moderna Inc  MRNA.O  rise 1.4% to
$147.47 premarket
    ** Co says its COVID-19 vaccine booster that targets both
the original coronavirus strain as well as Omicron produced
better immune response against the variant than its original
vaccine  urn:newsml:reuters.com:*:nL4N2XV2BB
    ** The booster raised virus-neutralizing antibodies
eightfold in a study - MRNA
    ** Co is submitting preliminary data to regulators and
expects Omicron-containing bivalent booster will be available in
late summer
    ** In May, co reiterated its prior forecast of $21 bln in
vaccine sales, and said it sees higher vaccine sales in H2 2022
than H1 2022  urn:newsml:reuters.com:*:nL3N2WW1O3
    ** MRNA shares down ~43% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))